secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cogent Biosciences, Inc. (COGT)
CIK:        0001622229
Form:       8-K/A
Filed at:   2022-06-16T23:59:59+00:00
Accession:  0001193125-22-175601
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cogent closes upsized $172.6M public offering of common stock and pre-funded warrants
--------------------------------------------------------------------------------

- Gross proceeds ~$172.6M from 17,899,698 shares at $8.25 and 3,030,302 pre-funded warrants at $8.24.
- Net proceeds to fund development and commercial activities for bezuclastinib and other candidates.
- Underwriters exercised in full their option to purchase 2,730,000 additional shares.
- Pre-funded warrants exercisable at $0.01 per share, subject to 9.99% beneficial ownership limitation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1622229/000119312522175601/0001193125-22-175601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1622229/000119312522175601/d357403d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-175601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer